TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Lindberg Life-Science AB
Closing information (x1000 DKK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
6
|
0
|
0 |
| Financial expenses |
46
|
0
|
152 |
| Earnings before taxes |
-145
|
6
|
-203 |
| EBITDA |
-83
|
-23
|
-31 |
| Total assets |
313
|
148
|
150 |
| Current assets |
120
|
6
|
28 |
| Current liabilities |
13
|
6
|
62 |
| Equity capital |
300
|
142
|
82 |
| - share capital |
34
|
33
|
36 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
95.8%
|
95.9%
|
54.7% |
| Turnover per employee | |||
| Profit as a percentage of turnover | -2416.7% | ||
| Return on assets (ROA) |
-31.6%
|
4.1%
|
-34.0% |
| Current ratio |
923.1%
|
100%
|
45.2% |
| Return on equity (ROE) |
-48.3%
|
4.2%
|
-247.6% |
| Change turnover |
6
|
0
|
-87 |
| Change turnover % | -100% | ||
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.